Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Svenja HappeClaudia Trenkwalder

Abstract

Challenge with low-dose apomorphine causes a significant rise in growth hormone (GH) in patients with Parkinson's disease (PD) compared to controls and patients with multiple system atrophy (MSA) who have not previously received dopaminergic treatment. To date, it has not been demonstrated whether an apomorphine-induced rise in GH can still be detected in PD patients who are currently treated with levodopa. We investigated whether an ongoing treatment with levodopa influences the GH response to subcutaneously applied low-dose apomorphine in PD patients. We studied 44 patients with idiopathic PD using the low-dose apomorphine test. Twenty-three patients were under treatment with levodopa and 21 patients were without any dopaminergic therapy. GH and cortisol levels were analyzed at time of injection and 45 minutes and 60 minutes after subcutaneous apomorphine injection. Forty-five minutes after apomorphine injection, there was no significant difference between the mean rise in plasma GH in untreated PD patients compared with levodopa-treated patients (P = 0.235). There was no increase of cortisol levels in each treatment group. Age, sex, duration, and severity of the disease did not show a covariate effect with GH levels. A small...Continue Reading

References

Jan 1, 1977·Transactions of the American Neurological Association·H L KlawansW J Weiner
Feb 1, 1977·Journal of Neurology, Neurosurgery, and Psychiatry·A Galea-DebonoJ Walters
Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Aug 1, 1991·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A H RajputA Rajput
Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·W R Gibb, A J Lees
May 1, 1967·Neurology·M M Hoehn, M D Yahr
Jun 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·T H CornS A Checkley
Feb 18, 1995·BMJ : British Medical Journal·N Quinn
Sep 28, 1998·Annals of Neurology·D J Brooks
Dec 30, 1998·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·S GilmanG Wenning
Jan 23, 1999·Journal of the Autonomic Nervous System·S GilmanG K Wenning
Sep 16, 2000·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·J D Veldhuis
Oct 14, 2000·Journal of Neurology, Neurosurgery, and Psychiatry·C E Clarke, P Davies
Aug 7, 2001·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·M T PellecchiaA Filla
Mar 26, 2002·Brain : a Journal of Neurology·Andrew J HughesAndrew J Lees
May 28, 2003·Journal of Neural Transmission·V KaasinenJ O Rinne

❮ Previous
Next ❯

Citations

Aug 26, 2006·Journal of Neural Transmission·T MüllerS Muhlack
Apr 7, 2007·Clinical Neuropharmacology·Thomas Müller, Siegfried Muhlack
May 22, 2007·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Svenja HappeClaudia Trenkwalder
Oct 31, 2018·Journal of Neural Transmission·Nayron Medeiros SoaresCarlos R M Rieder

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.